RADIANT-4: Results of international trial show promise in the treatment of neuroendocrine tumours

Share :
Published: 27 Sep 2015
Views: 3982
Rating:
Save
Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA

Prof Yao presents the results of his study which has shown that the mTOR inhibitor, everolimus, can delay tumour growth among both gastrointestinal and lung NETs, at a press conference at ECC 2015.

The results of this phase III study have shown that the mTOR inhibitor everolimus can delay tumour growth among patients with both advanced, progressive, non-functional gastrointestinal (GI) and lung neuroendocrine tumours (NETs).

Around 75% of NETS are non-functional meaning that they do not produce any specific hormones and the population of patients with non-functional GI and lung NETS has a limited number of treatment options.
Indeed, no other agents have been approved or have shown any significant efficacy in these tumours before everolimus in the RADIANT-4 study.

Watch the interview or read the news story for more.